172 related articles for article (PubMed ID: 18849638)
1. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration.
Jonas JB; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Libondi T; Spandau UH; Vossmerbaeumer U
Ophthalmic Res; 2009; 41(1):21-7. PubMed ID: 18849638
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
[TBL] [Abstract][Full Text] [Related]
3. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.
Jonas JB; Degenring RF; Kreissig I; Friedemann T; Akkoyun I
Eye (Lond); 2005 Feb; 19(2):163-70. PubMed ID: 15218517
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
7. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.
Jonas JB; Akkoyun I; Budde WM; Kreissig I; Degenring RF
Arch Ophthalmol; 2004 Feb; 122(2):218-22. PubMed ID: 14769599
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.
Wu WC; Cheng KC; Wu HJ
Eye (Lond); 2009 Dec; 23(12):2215-22. PubMed ID: 19218991
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.
Jonas JB; Kreissig I; Degenring RF
Br J Ophthalmol; 2004 Dec; 88(12):1557-62. PubMed ID: 15548812
[TBL] [Abstract][Full Text] [Related]
12. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
Jonas JB; Tao Y; Schlichtenbrede FC
J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
15. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
16. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
Schaal S; Kaplan HJ; Tezel TH
Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results.
Colucciello M
J Ocul Pharmacol Ther; 2008 Feb; 24(1):15-24. PubMed ID: 18201136
[TBL] [Abstract][Full Text] [Related]
18. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type.
Jonas JB; Libondi T; Ihloff AK; Harder B; Kreissig I; Schlichtenbrede F; Sauder G; Spandau UH
Acta Ophthalmol Scand; 2007 Aug; 85(5):563-5. PubMed ID: 17324219
[TBL] [Abstract][Full Text] [Related]
19. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.
Danis RP; Ciulla TA; Pratt LM; Anliker W
Retina; 2000; 20(3):244-50. PubMed ID: 10872928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
